Disruption of the p53-p53R2 DNA repair system in ulcerative colitis contributes to colon tumorigenesis

International Journal of Cancer

Volumn 118, Issue 6, 2006, Pages 1395-1403

  Yoshida, Tsutomu ^a   Haga, Shiori ^a   Numata, Yoshiko ^a   Yamashita, Kazuya ^b   Mikami, Tetuo ^a   Ogawa, Taishi ^a   Ohkusa, Toshifumi ^c   Okayasu, Isao ^a,b  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY HOSPITAL   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

DNA repair; p53; p53R2; Ulcerative colitis associated carcinoma

Indexed keywords

DNA; PROTEIN P53; SMALL INTERFERING RNA; TRITIUM;

ADULT; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; COLON CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; DNA REPAIR; DNA SEQUENCE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BUTYRIC ACIDS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; DISEASE PROGRESSION; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOTIDE REDUCTASES; RNA, SMALL INTERFERING; SUCCINIC ACID; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33644518370     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21538     Document Type: Article

References (40)

1. Blackstone MO, Riddell RH, Rogers BH, Levin B. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology 1981;80:366-74.
2. Collins RH, Jr, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review. N Engl J Med 1987;316:1654-8.
3. Lennard-Jones JE, Melville DM, Morson BC, Ritchie JK, Williams CB. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 1990;31:800-6.
4. Okayasu I, Fujiwara M, Takemura T, Toyoshima H, Nakamura K. Development of colorectal cancer in ulcerative colitis, clinicopathological study of 347 patients and new concepts of cancer. Development from analysis of mucosal cell proliferation activity. Stomach and Intestine (Tokyo) 1993;28:171-9.
5. Okayasu I, Hana K, Yoshida T, Mikami T, Kanno J, Fujiwara M. Significant increase of colonic mutated crypts in ulcerative colitis correlatively with duration of illness. Cancer Res 2002;62:2236-8.
6. Singer II, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, Stenson WF. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996;111:871-85.
7. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 1998;115:297-306.
8. Willenbucher RF, Aust DE, Chang CG, Zelman SJ, Ferrell LD, Moore DH, II, Waldman FM. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol 1999;154:1825-30.
9. Aust DE, Willenbucher RF, Terdiman JP, Ferrell LD, Chang CG, Moore DH, II, Molinaro-Clark A, Baretton GB, Loehrs U, Waldman FM. Chromosomal alterations in ulcerative colitis-related and sporadic colorectal cancers by comparative genomic hybridization. Hum Pathol 2000;31:109-14.
10. Willenbucher RF, Zelman SJ, Ferrell LD, Moore DH, II, Waldman FM. Chromosomal alterations in ulcerative colitis-related neoplastic progression. Gastroenterology 1997;113:791-801.
11. Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, Hontanosas M, Newkirk C, Meltzer SJ. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993;104:1633-9.
12. Yoshida T, Mikami T, Mitomi T, Okayasu I. Diverse p53 alterations in ulcerative colitis-associated low-grade dysplasia: full-length gene sequencing in microdissected single crypts. J Pathol 2003;199:166-75.
13. Yoshida T, Matsumoto N, Mikami T, Okayasu I. Upregulation of p16(INK4A) and Bax in p53 wild/p53-overexpressing crypts in ulcerative colitis-associated tumours. Br J Cancer 2004;91:1081-8.
14. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000;404:42-9.
15. Guittet O, Hakansson P, Voevodskaya N, Fridd S, Graslund A, Arakawa H, Nakamura Y, Thelander L. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 2001;276:40647-51.
16. Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl 2001;234:29-40.
17. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003;52:79-83.
18. Deacon AG, Duerden BI, Holbrook WP, Gas-liquid Chromatographic analysis of metabolic products in the identification of bacteroidaceae of clinical interest. J Med Microbiol 1978;11:81-99.
19. Rotstein OD, Pruett TL, Fiegel VD, Nelson RD, Simmons RL. Succinic acid, a metabolic by-product of Bacteroides species, inhibits polymorphonuclear leukocyte function. Infect Immun 1985;48:402-8.
20. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987;28:1221-7.
21. Scheppach W. Effects of short chain fatty acids on gut morphology and function. Gut 1994;35:S35-8.
22. Simpson EJ, Chapman MA, Dawson J, Berry D, Macdonald IA, Cole A. In vivo measurement of colonic butyrate metabolism in patients with quiescent ulcerative colitis. Gut 2000;46:73-7.
23. Avivi-Green C, Polak-Charcon S, Madar Z, Schwartz B. Different molecular events account for butyrate-induced apoptosis in two human colon cancer cell lines. J Nutr 2002;132:1812-8.
24. Pellizzaro C, Coradini D, Daniotti A, Abolafio G, Daidone MG. Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines. Int J Cancer 2001;91:654-7.
25. Tabuchi Y, Arai Y, Kondo T, Takeguchi N, Asano S. Identification of genes responsive to sodium butyrate in colonic epithelial cells. Biochem Biophys Res Commun 2002;293:1287-94.
26. Ariake K, Ohkusa T, Sakurazawa T, Kumagai J, Eishi Y, Hoshi S, Yajima T. Roles of mucosal bacteria and succinic acid in colitis caused by dextran sulfate sodium in mice. J Med Dent Sci 2000;47:233-41.
27. Arai N, Mitomi H, Ohtani Y, Igarashi M, Kakita A, Okayasu I. Enhanced epithelial cell turnover associated with p53 accumulation and high p21WAF1/CIP1 expression in ulcerative colitis. Mod Pathol 1999;12:604-11.
28. Yamashita K, Yasuda S, Kuba T, Otani Y, Fujiwara M, Okayasu I. Unique characteristics of rectal carcinoma cell lines derived from invasive carcinomas in ulcerative colitis patients. Cancer Sci 2004;95:211-7.
29. Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y, Frazier ML. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 1999;117:350-8.
30. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14:931-68.
31. Yoshida T, Higuchi T, Hagiyama H, Strasser A, Nishioka K, Tsubata T. Rapid B cell apoptosis induced by antigen receptor ligation does not require Fas (CD95/APO-1), the adaptor protein FADD/MORT1 or CrmA-sensitive caspases but is defective in both MRL-+/+ and MRL-1pr/1pr mice. Int Immunol 2000;12:517-26.
32. Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura Y, Arakawa H. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 2001;61:8256-62.
33. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000;102:849-62.
34. Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y, Monden M, Nakamura Y. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell 2001;8:85-94.
35. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, Harris CC. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000;60:3333-7.
36. Cross RK, Wilson KT. Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis 2003;9:179-89.
37. Sandborn W, Tremaine W, Schroeder K, Batts K, Lawson G, Steiner B, Harrison J, Zinsmeister A. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994;106:1429-35.
38. Mikami T, Yoshida T, Akino F, Motoori T, Yajima M, Okayasu I. Apoptosis regulation differs between ulcerative colitis-associated and sporadic colonie tumors: association with survivin and Bcl-2. Am J Clin Pathol 2003;119:723-30.
39. Papadopoulos N, Lindblom A. Molecular basis of HNPCC: mutations of MMR genes. Hum Mutat 1997;10:89-99.
40. Bruewer M, Schmid KW, Krieglstein CF, Senninger N, Schuermann G. Metallothionein: early marker in the carcinogenesis of ulcerative colitis-associated colorectal carcinoma. World J Surg 2002;26:726-31.